Profile data is unavailable for this security.
About the company
Fractyl Health, Inc. is a metabolic therapeutics company. The Company is focused on approaches to the treatment of metabolic diseases, including type 2 diabetes (T2D) and obesity. The Revita DMR System (Revita), the Company’s lead product candidate, is an outpatient procedural therapy designed to durably modify duodenal dysfunction, a pathologic consequence of a high fat and high sugar diet, which can initiate T2D and obesity in humans. The Revita system is designed to enable durable and repeatable metabolic improvement via hydrothermal ablation of the dysfunctional duodenal mucosa to address duodenal pathology and consequent metabolic disease progression directly. The Company is involved in enrolling is pivotal Revitalize-1 study in patients with inadequately controlled T2D. It is also developing Rejuva, a locally administered, adeno-associated virus (AAV), delivered pancreatic gene therapy (PGTx), platform. Rejuva is designed to enable long-term remission of T2D and obesity.
- Revenue in USD (TTM)119.00k
- Net income in USD-65.88m
- Incorporated2010
- Employees102.00
- LocationFractyl Health Inc3 Van De Graaff Drive, Suite 200BURLINGTON 01803United StatesUSA
- Phone+1 (781) 902-8800
- Fax+1 (302) 655-5049
- Websitehttps://www.fractyl.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Checkpoint Therapeutics Inc | 78.00k | -42.47m | 106.69m | 23.00 | -- | -- | -- | 1,367.85 | -1.50 | -1.50 | 0.0027 | -0.372 | 0.0111 | -- | 2.17 | 3,391.30 | -606.33 | -142.43 | -- | -342.79 | -- | -- | -54,444.87 | -6,554.97 | -- | -- | -- | -- | -46.35 | -50.61 | 17.21 | -- | -- | -- |
Invivyd Inc | 2.26m | -203.84m | 108.27m | 94.00 | -- | 0.7699 | -- | 47.82 | -1.80 | -1.80 | 0.0199 | 1.18 | 0.0092 | -- | 1.13 | 24,085.11 | -82.73 | -- | -96.25 | -- | 96.11 | -- | -9,003.40 | -- | 4.57 | -- | 0.00 | -- | -- | -- | 17.68 | -- | -- | -- |
Annovis Bio Inc | 0.00 | -43.02m | 108.74m | 6.00 | -- | -- | -- | -- | -4.42 | -4.42 | 0.00 | -0.1494 | 0.00 | -- | -- | 0.00 | -308.78 | -106.31 | -395.89 | -124.71 | -- | -- | -- | -- | -- | -51.53 | -- | -- | -- | -- | -121.90 | -- | -- | -- |
CervoMed Inc | 9.65m | -5.04m | 109.03m | 8.00 | -- | 2.18 | -- | 11.29 | -0.4796 | -0.4796 | 1.55 | 6.06 | 0.2803 | -- | -- | 1,206,660.00 | -14.64 | -53.67 | -15.71 | -58.89 | -- | -- | -52.24 | -949.54 | -- | -- | 0.00 | -- | -- | -- | 86.07 | -- | -- | -- |
Clearside Biomedical Inc | 7.52m | -33.46m | 110.62m | 30.00 | -- | -- | -- | 14.70 | -0.497 | -0.497 | 0.1119 | -0.3785 | 0.2058 | -- | 59.01 | 250,800.00 | -91.51 | -63.57 | -107.97 | -81.77 | 95.06 | -- | -444.66 | -231.80 | -- | -- | -- | -- | 519.89 | 207.34 | 1.40 | -- | 82.41 | -- |
Prelude Therapeutics Inc | 0.00 | -129.85m | 112.25m | 128.00 | -- | 0.4718 | -- | -- | -1.80 | -1.80 | 0.00 | 4.32 | 0.00 | -- | -- | 0.00 | -51.44 | -47.21 | -55.69 | -51.07 | -- | -- | -- | -- | -- | -- | 0.0028 | -- | -- | -- | -5.54 | -- | 46.03 | -- |
Nuvectis Pharma Inc | 0.00 | -21.10m | 112.48m | 13.00 | -- | 9.02 | -- | -- | -1.29 | -1.29 | 0.00 | 0.6682 | 0.00 | -- | -- | 0.00 | -97.61 | -- | -128.44 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -16.64 | -- | -- | -- |
Fractyl Health Inc | 119.00k | -65.88m | 114.55m | 102.00 | -- | 1.62 | -- | 962.57 | -1.37 | -1.37 | 0.0025 | 1.48 | 0.0013 | 1.02 | 3.05 | 1,166.67 | -59.97 | -- | -67.93 | -- | 41.18 | -- | -46,620.17 | -- | 7.46 | -- | 0.2862 | -- | -- | -- | -48.15 | -- | -- | -- |
Rani Therapeutics Holdings Inc | 0.00 | -30.58m | 116.96m | 140.00 | -- | 39.09 | -- | -- | -1.18 | -1.18 | 0.00 | 0.056 | 0.00 | -- | -- | 0.00 | -95.14 | -- | -154.95 | -- | -- | -- | -- | -- | -- | -21.58 | 0.8416 | -- | -- | -- | -11.06 | -- | -- | -- |
Skye Bioscience Inc | 0.00 | -42.29m | 117.41m | 11.00 | -- | 1.49 | -- | -- | -3.91 | -3.91 | 0.00 | 2.59 | 0.00 | -- | -- | 0.00 | -94.50 | -232.67 | -129.40 | -- | -- | -- | -- | -- | -- | -323.10 | 0.0626 | -- | -- | -- | -93.23 | -- | 23.38 | -- |
Verastem Inc | 10.00m | -89.49m | 117.51m | 73.00 | -- | 4.16 | -- | 11.75 | -3.34 | -3.34 | 0.3726 | 1.49 | 0.0672 | -- | 2.00 | 136,986.30 | -60.16 | -62.70 | -72.65 | -75.18 | -- | -- | -894.91 | -406.17 | -- | -- | 0.5052 | -- | -100.00 | -- | -18.36 | -- | -- | -- |
Seres Therapeutics Inc | 374.00k | -162.11m | 117.53m | 233.00 | -- | -- | -- | 314.26 | -1.18 | -1.18 | 0.0027 | -0.5742 | 0.001 | -- | 0.0286 | 1,605.15 | -44.53 | -41.51 | -59.82 | -54.13 | -- | -- | -43,343.58 | -170.14 | 0.889 | -17.64 | 6.65 | -- | 1,672.24 | 34.91 | 54.54 | -- | 32.72 | -- |
INmune Bio Inc | 85.00k | -37.74m | 117.74m | 11.00 | -- | 2.82 | -- | 1,385.13 | -2.06 | -2.06 | 0.0046 | 1.88 | 0.0014 | -- | 0.0311 | 7,727.27 | -61.78 | -37.82 | -80.24 | -41.86 | -- | -- | -44,402.35 | -14,901.03 | -- | -23.01 | 0.1184 | -- | -58.56 | -- | -9.92 | -- | -- | -- |
Adicet Bio Inc | 0.00 | -137.29m | 117.83m | 143.00 | -- | 0.5012 | -- | -- | -2.53 | -2.53 | 0.00 | 2.85 | 0.00 | -- | -- | 0.00 | -50.25 | -37.03 | -53.87 | -40.28 | -- | -- | -- | -748.46 | -- | -- | 0.00 | -- | -100.00 | -- | -104.41 | -- | 65.27 | -- |
Quantum-Si Inc | 1.70m | -89.35m | 119.18m | 159.00 | -- | 0.5108 | -- | 70.03 | -0.6302 | -0.6302 | 0.012 | 1.64 | 0.0057 | 0.2321 | 3.68 | 10,704.40 | -29.89 | -- | -30.99 | -- | 53.41 | -- | -5,249.65 | -- | 20.13 | -- | 0.00 | -- | -- | -- | 27.55 | -- | -- | -- |
Coherus Biosciences Inc | 308.13m | -29.34m | 119.82m | 246.00 | -- | -- | -- | 0.3889 | -0.4014 | -0.4014 | 2.74 | -0.7301 | 0.5385 | 2.86 | 1.95 | 1,006,974.00 | -5.13 | -21.43 | -11.46 | -29.32 | 41.51 | 79.01 | -9.52 | -36.56 | 1.07 | -4.02 | 1.47 | -- | 21.89 | -- | 18.46 | -- | -18.37 | -- |
Holder | Shares | % Held |
---|---|---|
Maverick Capital Ltd.as of 31 Mar 2024 | 4.25m | 8.88% |
M28 Capital Management LPas of 31 Mar 2024 | 1.86m | 3.88% |
Citadel Advisors LLCas of 31 Mar 2024 | 1.70m | 3.55% |
Corebridge Institutional Investments (US) LLCas of 31 Mar 2024 | 1.34m | 2.80% |
Massachusetts Financial Services Co.as of 30 Jun 2024 | 996.38k | 2.08% |
Ensign Peak Advisors, Inc.as of 31 Mar 2024 | 834.25k | 1.74% |
683 Capital Management LLCas of 31 Mar 2024 | 750.00k | 1.57% |
Millennium Management LLCas of 31 Mar 2024 | 382.31k | 0.80% |
Balyasny Asset Management LPas of 31 Mar 2024 | 314.06k | 0.66% |
Morgan Stanley Smith Barney LLC (Investment Management)as of 31 Mar 2024 | 271.81k | 0.57% |